Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award

Published on by Research Hypothesis

Dr. Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award

Dr. Zeinab Mohsenipour | Biology and Life Sciences | Women Researcher Award | Postdoctoral Researcher | Tehran University of Medical Sciences | Iran

Dr. Zeinab Mohsenipour is a distinguished Iranian microbiologist whose scholarly focus and scientific achievements have advanced the field of Medical Bacteriology, particularly in the areas of antimicrobial resistance, bacterial biofilms, and bacteriophage therapy. She earned her Ph.D. in Medical Bacteriology from Tehran University of Medical Sciences, building on her earlier academic foundation with an M.Sc. in Microbiology and a B.A. in Biology from Shahid Bahonar University of Kerman. Throughout her academic and research journey, Dr. Mohsenipour has demonstrated an unwavering commitment to exploring the molecular and clinical mechanisms underlying infectious diseases. Her professional experience encompasses serving as a Research Assistant in the Bacteriology Laboratory at Tehran University of Medical Sciences and as a Lecturer at the University of Science and Culture, where she has taught undergraduate courses in microbial physiology, medical bacteriology, and microbial diversity. Beyond academia, she has also held an industry leadership role as Sales Manager at NojanTeb Azma Company, gaining practical insight into the intersection of scientific innovation and healthcare product development. Her research interests center on the study of antibiotic-resistant pathogens, biofilm inhibition, natural antimicrobial compounds, and the therapeutic application of predatory bacteria and bacteriophages. Dr. Mohsenipour possesses an extensive range of research skills, including bacterial culture and identification, PCR and molecular cloning, antibiotic susceptibility testing, and animal model experimentation, all of which contribute to her capacity for translational biomedical research. Her scientific productivity is evidenced by her numerous peer-reviewed publications in reputable journals indexed in Scopus, Frontiers, and BMC, addressing urgent microbiological issues such as lung infection models and bacterial-based drug delivery systems. Dr. Mohsenipour has also co-authored scientific books that enrich microbiological education, including An Overview of Monoclonal Antibodies: Production Methods and Applications and The Principle of Microbial Physiology. Her contributions have been recognized through invitations to serve as a reviewer for the European Journal of Clinical and Biomedical Sciences and through memberships in esteemed professional societies such as the American Society for Microbiology (ASM) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Dr. Mohsenipour’s excellence in both teaching and research reflects her passion for nurturing scientific inquiry and innovation. Her continuous involvement in international collaborations, advanced workshops, and cutting-edge bacteriological projects underscores her role as a promising and impactful researcher who is shaping the future of microbial science and global health improvement.

Profile: Scopus | ORCID | Google Scholar

Featured Publications 

  1. Mohsenipour, Z., & Hassanshahian, M. (2015). The inhibitory effect of Thymus vulgaris extracts on the planktonic form and biofilm structures of six human pathogenic bacteria. Avicenna Journal of Phytomedicine, 5(4), 309–318. (Citations: 94)

  2. Mohsenipour, Z., & Hassanshahian, M. (2015). The effects of Allium sativum extracts on biofilm formation and activities of six pathogenic bacteria. Jundishapur Journal of Microbiology, 8(8), e18971. (Citations: 78)

  3. Mohsenipour, Z., & Hassanshahian, M. (2016). Antibacterial activity of Euphorbia hebecarpa alcoholic extracts against six human pathogenic bacteria in planktonic and biofilm forms. Jundishapur Journal of Microbiology, 9(6), e34701. (Citations: 63)

  4. Omidinia, E., Shahbazmohammadi, H., & Mohsenipour, Z. (2019). Partitioning of recombinant Pseudomonas putida POS-F84 proline dehydrogenase in aqueous two-phase systems: Optimization using response surface methodology. Applied Biochemistry and Biotechnology, 189, 498–510. (Citations: 32)

  5. Tajabadi, F. H., Karimian, S. M., Mohsenipour, Z., et al. (2022). Biocontrol treatment: Application of Bdellovibrio bacteriovorus HD100 against burn wound infection caused by Pseudomonas aeruginosa in mice. Burns: Journal of the International Society for Burn Injuries. (Citations: 19)

  6. Mohsenipour, Z., Arazi, P., Skurnik, M., et al. (2024). Predation on bacterial pathogens by predatory bacteria of sewage origin: Three days prey-predator interactions. BMC Microbiology, 24, 516. (Citations: 12)

  7. Mohsenipour, Z., Kianian, F., Jahanbin, B., Abtahi, H. R., Ghazanfari, T., Edalatifard, M., Amanpour, S., Skurnik, M., Arazi, P., & Feizabadi, M. M. (2025). Predatory bacteria can intensify lung injury in a multidrug-resistant Acinetobacter baumannii pneumonia model in rat. Frontiers in Microbiology, 16, 1512119. (Citations: 7)

 

Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award | Pharmaceutical | Abdul Wali Khan University Mardan | Pakistan

Dr. Muhammad Bilal Afridi is a dedicated pharmaceutical scientist and clinical pharmacist recognized for his expertise in drug synthesis, pharmacological modeling, and computational chemistry. With a profound academic background and more than a decade of professional experience, Dr. Afridi has established himself as a leading researcher in the domain of synthetic and therapeutic drug development. He earned his Ph.D. in Pharmaceutical Sciences from Abdul Wali Khan University, Mardan, where his doctoral research focused on the synthesis, characterization, computational studies, and pharmacological potential of synthetic curcumin derivatives aimed at addressing diabetes and amnesia-related disorders. His earlier academic milestones include an M.Phil in Pharmaceutical Sciences from Abdul Wali Khan University and a Doctor of Pharmacy (Pharm-D) from Kohat University of Science and Technology. Professionally, Dr. Muhammad Bilal Afridi has served as a pharmacist at the Institute of Kidney Diseases (IKD), Peshawar, where he managed hospital pharmacy operations, clinical pharmacy services, and patient safety programs. His leadership extended to training junior pharmacists, supervising pharmacy interns, and participating in institutional Drug and Therapeutic Committees. His previous tenures at Rehman Medical Institute and D. Watson Chemist allowed him to develop robust skills in patient counseling, prescription review, pharmacovigilance, and rational drug use. Dr. Afridi’s research interests encompass computational drug design, molecular docking, pharmacodynamics, and synthesis of bioactive compounds, reflecting his interdisciplinary approach that bridges chemistry, pharmacology, and computational biology. His published works in highly regarded journals, including Computational Biology and Chemistry, Inorganic Chemistry Communications, and Current Molecular Pharmacology, contribute significantly to advancing medicinal chemistry and pharmaceutical innovation. He has demonstrated strong analytical and technical skills in density functional theory (DFT) modeling, ADMET prediction, and spectral analysis. Dr. Muhammad Bilal Afridi’s professional competencies include teaching, mentoring, research supervision, and scientific writing, backed by proficiency in tools like EndNote and MS Office. His contributions have been acknowledged through multiple peer-reviewed publications, collaborations with international researchers from Türkiye and Saudi Arabia, and recognition in academic circles for his commitment to scientific excellence. He continues to serve as a role model for young researchers in Pakistan through his dedication to patient-centered research and academic mentorship. His unwavering commitment to bridging pharmaceutical sciences and clinical applications makes him a strong candidate for recognition in global research excellence. Dr. Muhammad Bilal Afridi stands as an emerging leader with a promising future in international pharmaceutical research, committed to innovation, integrity, and impactful contributions to human health and medicine.

Profile: Scopus

Featured Publications 

  1. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). SwissADME studies and density functional theory (DFT) approaches of methyl substituted curcumin derivatives. Computational Biology and Chemistry, 112, 108153. (Cited by 8)

  2. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives. Inorganic Chemistry Communications, 168, 112943. (Cited by 6)

  3. Afridi, M. B., Khan, H., Ali Shah, S. W., Zafar, M., Almalki, A. S., Ghias, M., & Rahman, N. (2022). In-vivo anti-nociceptive activities of Schiff bases aldehyde derivatives of 4-aminoantipyrine and their molecular docking studies. Main Group Chemistry, 21(2), 373–386. (Cited by 10)

  4. Afridi, M. B., Khan, H., Akkol, E. K., & Aschner, M. (2021). Pain perception and management: Where do we stand? Current Molecular Pharmacology, 14(5), 678–688. (Cited by 25)

  5. Afridi, M. B., Sardar, H., Shah, S. W. A., Serdaroğlu, G., & Khan, H. (2025). Exploring anticholinergic and anti-amnesic potential of methyl substituted monocarbonyl curcumin derivatives. European Journal of Pharmacology, 950, 182653. (Cited by 2)

  6. Afridi, M. B., Khan, H., & Shah, S. W. A. (2023). Computational evaluation of synthetic curcumin analogs for neuroprotective potential using molecular docking approaches. Journal of Molecular Structure, 1287, 135623. (Cited by 4)

  7. Afridi, M. B., Sardar, H., & Khan, H. (2023). Pharmacological insights into curcumin derivatives: A computational and experimental perspective. Bioorganic Chemistry, 137, 106707. (Cited by 3)